{"gene":"GDF2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2005,"finding":"BMP9 (GDF2) crystal structure resolved to 2.3 Å; the pro-region remains tightly associated with BMP9 after secretion but does not inhibit receptor binding or biological activity in cell-based assays. ALK1 identified as a receptor for BMP9 by surface plasmon resonance (BIAcore) and functional neutralization with soluble ALK1.","method":"X-ray crystallography (2.3 Å), surface plasmon resonance (BIAcore), cell-based activity assays with soluble ALK1 as ligand trap","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with SPR binding assays and functional cell-based assays in a single rigorous study","pmids":["15851468"],"is_preprint":false},{"year":2007,"finding":"BMP9 binds with high affinity to ALK1 and endoglin, and weakly to ALK2 and BMPR-II/ActR-II in transfected COS cells; in endothelial cells BMP9 signals predominantly via ALK1 and BMPR-II, activating Smad1/5 and inducing ID1 protein and endoglin mRNA. BMP9 inhibits bFGF-stimulated endothelial cell proliferation/migration and blocks VEGF-induced angiogenesis.","method":"Receptor-binding assays in transfected COS cells, western blot (Smad1/5 phosphorylation), qRT-PCR, endothelial cell proliferation/migration assays, in vivo angiogenesis assay","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (binding, signaling, functional), replicated across labs","pmids":["17311849"],"is_preprint":false},{"year":2010,"finding":"BMP9 induces NGF expression selectively in cholinergic (Chat-positive/p75-positive) basal forebrain neurons via ALK1; secreted NGF acts in an autocrine/paracrine manner to support acetylcholine production and ChAT gene expression. BMP9-induced Ngf expression requires new protein synthesis and is blocked by BMP type I receptor inhibition.","method":"Primary embryonic septal cell culture, FACS isolation of cholinergic neurons (GFP/p75), RT-PCR, pharmacological inhibition of BMP type I receptors, NGF ELISA","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FACS-based cell sorting with functional assays in one lab, single study","pmids":["20554873"],"is_preprint":false},{"year":2010,"finding":"IGF-2 potentiates BMP9-induced osteogenic differentiation of mesenchymal stem cells by enhancing BMPR-Smad reporter activity and Smad1/5/8 nuclear translocation via PI3K/AKT signaling; PI3K inhibitor LY294002 abolishes this cross-talk and directly inhibits BMP9 activity.","method":"Alkaline phosphatase activity assay, Smad reporter assays, Smad1/5/8 nuclear translocation (immunofluorescence), pharmacological PI3K inhibition, ectopic bone formation in vivo","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays (reporter, nuclear translocation, in vivo bone formation), single lab","pmids":["20499340"],"is_preprint":false},{"year":2012,"finding":"BMP9 is required for postnatal retinal vascular remodeling; neutralizing anti-BMP9 antibody increases retinal vascular density. BMP9 promotes endothelial quiescence and upregulates Notch pathway genes (Jagged1, Dll4, Hey1, Hey2, Hes1) while decreasing apelin expression in endothelial cells.","method":"Neutralizing antibody treatment in neonatal mice, Bmp9-KO mice, retinal vascular morphometry, gene expression analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and antibody neutralization in vivo with molecular pathway validation, replicated findings","pmids":["22566602"],"is_preprint":false},{"year":2012,"finding":"BMP9 regulates the CXCL12/SDF1-CXCR4 chemokine axis in endothelial cells in an endoglin- and ALK1-dependent manner; RNA knockdown of endoglin or ALK1 impairs SDF1/CXCR4 regulation by BMP9 and impairs SDF1 expression in vivo in endoglin-deficient mice.","method":"cDNA microarray, quantitative mass spectrometry, siRNA knockdown of endoglin and ALK1, hindlimb ischemia mouse model","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (transcriptomics, proteomics, siRNA, in vivo), single lab","pmids":["23018639"],"is_preprint":false},{"year":2013,"finding":"BMP9 promotes proliferation and survival (anti-apoptotic function) in HepG2 hepatocellular carcinoma cells via autocrine signaling, activating Smad1/5/8 phosphorylation and Id1 upregulation; BMP9 also triggers cell cycle progression in these cells.","method":"siRNA knockdown, chemical inhibitors (ligand trap), proliferation assays, apoptosis assays (low-serum), Smad1/5/8 phosphorylation western blot","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA, chemical inhibitors and functional assays, single lab","pmids":["23936038"],"is_preprint":false},{"year":2013,"finding":"BMP9 controls lymphatic vessel maturation and valve formation via ALK1; Bmp9-KO mice show hyperplastic mesenteric collecting vessels retaining LYVE-1 expression, and BMP9 inhibits LYVE-1 expression in lymphatic endothelial cells in an ALK1-dependent manner. BMP9 upregulates valve formation genes (Foxc2, Connexin37, EphrinB2, Neuropilin1) in LECs.","method":"Bmp9-KO mice, lymphatic vessel morphometry, in vitro LEC treatment with BMP9, ALK1 dependency confirmed by inhibition, lymphatic drainage assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with in vitro mechanistic studies and lymphatic function assay","pmids":["23741013"],"is_preprint":false},{"year":2014,"finding":"BMP9 induces VSMC osteogenic differentiation and calcification via ALK1 and Smad-dependent pathways; BMP9 activates Smad1/5/8 and Smad2/3 phosphorylation, both of which bind Smad4 to activate target genes. Smad4 siRNA knockdown significantly reduces BMP9-induced ALP activity and calcium deposition.","method":"In vitro VSMC calcification assay, soluble ALK1 chimeric protein inhibition, Smad siRNA, ALP inhibitor, western blot for Smad phosphorylation","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and siRNA-based mechanistic dissection, single lab, multiple readouts","pmids":["25297851"],"is_preprint":false},{"year":2014,"finding":"BMP9 stability and activity are regulated by a redox-dependent mechanism: BMP9 dimers form with (D-form, disulfide-bonded) or without (M-form) an intermolecular disulfide bond, resolved by a 1.9 Å crystal structure. The M-form shows less sustained Smad1/5/8 phosphorylation and greater susceptibility to redox-dependent protease cleavage from serum.","method":"Chromatography, X-ray crystallography (1.9 Å), redox conversion assays, Smad1/5/8 phosphorylation kinetics, protease susceptibility assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with biochemical and signaling assays in one rigorous study","pmids":["25237187"],"is_preprint":false},{"year":2014,"finding":"BMP9 potently suppresses FSH-induced progesterone production in rat granulosa cells via a receptor complex of ALK1 and BMPR-II, activating Smad1/5/8 phosphorylation and Id-1 transcription; actions are not mediated by ALK2, ALK3, or ALK6 based on inhibitor analysis.","method":"Rat primary granulosa cell culture, ALK inhibitors, extracellular domain receptor constructs for receptor identification, Smad1/5/8 phosphorylation assay, cAMP measurement, steroidogenic gene expression","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological and molecular tools, receptor ECD blocking, single lab","pmids":["25527306"],"is_preprint":false},{"year":2015,"finding":"BMP9 and BMP10 are required for ductus arteriosus closure; Bmp9-KO mice show imperfect DA closure, and combined BMP10 neutralization causes reopening. The mechanism involves a defect in intimal cell differentiation from endothelium to mesenchyme with lack of extracellular matrix deposition; several genes involved in this process are regulated by BMP9 and BMP10.","method":"Bmp9-KO mice, neutralizing anti-BMP10 antibody, transmission electron microscopy, immunofluorescence, gene expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus antibody neutralization in vivo with multiple mechanistic readouts","pmids":["26056270"],"is_preprint":false},{"year":2015,"finding":"DLL4/Notch1 and BMP9/ALK1 signaling pathways are interdependent for induction of endothelial quiescence: canonical BMP9 signaling via ALK1-Smad1/5/9 is disrupted by Notch inhibition, and DLL4 activity is suppressed when basal ALK1-Smad pathway is inhibited. The combined pathway acts through P27KIP1 induction and thrombospondin-1 upregulation. Loss of Dll4 in vivo leads to compensatory upregulation of pSmad1/5/9.","method":"Human endothelial cell culture, Notch inhibitors, ALK1-Smad pathway inhibitors, proteomics, Dll4(+/-) mouse lung endothelial cell analysis","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway inhibition plus in vivo genetic model, single lab","pmids":["26471266"],"is_preprint":false},{"year":2015,"finding":"BMP9-induced endothelial quiescence requires endoglin expression; endoglin regulates subcellular localization of zyxin in focal adhesions in response to BMP9. BMP9-dependent nuclear localization of YAP1 (Hippo pathway transcriptional coactivator) occurs via endoglin, modulating expression of CCN1, CCN2, and CCL2.","method":"RNA knockdown of endoglin, confocal immunofluorescence of zyxin/YAP1 localization, gene expression analysis (YAP1 target genes)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with direct localization imaging and gene expression, single lab","pmids":["25909848"],"is_preprint":false},{"year":2015,"finding":"BMP9 induces EPC-to-endothelial cell differentiation and neovascularization via ALK1; blockade of ALK1 signaling impairs EPC-mediated neovascularization in a hindlimb ischemia model.","method":"Gene expression profiling of EPCs, in vitro ALK1-dependent differentiation assay, hindlimb ischemia mouse model, ALK1 signaling blockade","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo mechanistic studies with ALK1 pathway blockade, single lab","pmids":["26229139"],"is_preprint":false},{"year":2015,"finding":"In ovarian and breast epithelial cells, GDF2/BMP9 activates the SMAD1/5 signaling axis through increased complex formation between ALK3/ALK6 (type I receptors) and BMPRII (type II receptor); this activation promotes anoikis sensitivity and suppresses anchorage-independent growth, independent of SMAD2 cross-talk. GDF2 promoter methylation silences this tumor-suppressive function in cancer cell lines.","method":"Receptor co-immunoprecipitation, SMAD1/5 phosphorylation assays, anchorage-independent growth assays, promoter methylation analysis","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor complex co-IP with functional anoikis assays, single lab","pmids":["26678910"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of the human endoglin ectodomain in complex with BMP9 resolved; BMP9 interacts with a hydrophobic surface of the N-terminal orphan domain of endoglin. The interface involves HHT1-mutated residues and overlaps with the TRC105 antibody epitope. Structurally, two endoglin copies embrace homodimeric BMP9 in a manner compatible with type I but not type II receptor binding.","method":"X-ray crystallography of ENG ectodomain and ENG:BMP9 complex","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with direct mapping of disease-relevant interface residues and receptor compatibility","pmids":["28564608"],"is_preprint":false},{"year":2017,"finding":"BMP9 stimulates ET-1 release from human pulmonary artery endothelial cells via Smad1 and p38 MAPK, independent of the canonical Smad4 pathway; ALK1 or BMPR-II knockdown attenuates BMP9-stimulated ET-1 release. BMP9-induced ET-1 is involved in inhibition of endothelial cell migration and promotion of tubule formation.","method":"Western blot, RT-PCR, ELISA, siRNA knockdown of ALK1 and BMPR-II, migration assay, tubule formation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple functional assays, single lab","pmids":["22299030"],"is_preprint":false},{"year":2017,"finding":"BMP9 promotes liver fibrosis via SMAD/ID1 signaling directly in hepatic stellate cells; hepatic stellate cells (quiescent and activated) are identified as major BMP9-producing cells in the liver. Adenovirus-mediated Bmp9 knockdown or BMP9 antagonist ALK1-Fc attenuates fibrosis in chronic liver injury mouse models.","method":"Primary liver cell culture, BMP9 stimulation of HSCs and hepatocytes, partial hepatectomy and CCl4 mouse models, adenoviral Bmp9 knockdown, anti-BMP9 monoclonal antibody, SMAD signaling western blot","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple in vitro and in vivo models with genetic and antibody-based loss of function, identifying HSCs as the cellular source","pmids":["28336518"],"is_preprint":false},{"year":2018,"finding":"BMP9/ALK1 signaling prevents hyperglycemia-induced vascular permeability by preventing VEGF-induced VE-cadherin phosphorylation and by inducing occludin expression; ALK1 haploinsufficiency worsens vascular leakage in diabetic mice, and adenoviral BMP9 delivery reduces retinal barrier dysfunction.","method":"In vitro hyperglycemic endothelial cell model, streptozotocin diabetic mouse model, Alk1 haploinsufficient mice, adenoviral BMP9 delivery, VE-cadherin phosphorylation western blot, occludin expression assay","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models with defined molecular mechanism, single lab","pmids":["29880487"],"is_preprint":false},{"year":2018,"finding":"BMP9-induced osteoblastic differentiation in MSCs requires functional Notch signaling; Notch inhibitor and dominant-negative Notch1 inhibit BMP9-induced osteogenic differentiation in vitro and ectopic bone formation in vivo. BMP9 upregulates expression of Notch receptors and ligands at the intermediate stage of osteogenic differentiation, while early-responsive BMP9 target genes are not affected by Notch disruption.","method":"Notch inhibitor treatment, dominant-negative Notch1 expression, Notch pathway genetic disruption, in vivo ectopic bone formation, gene expression analysis","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic disruption with in vivo validation, single lab","pmids":["30353129"],"is_preprint":false},{"year":2019,"finding":"Soluble endoglin (sENG) purified from human placenta and plasma is primarily monomeric; monomeric sENG binds circulating prodomain-bound BMP9, causing prodomain release and formation of a sENG:BMP9 complex. This complex signals with comparable potency and specificity to BMP9 alone on endothelial cells; full signaling requires transmembrane ENG. Thus sENG does not act as an inhibitory ligand trap for BMP9.","method":"Protein purification, biochemical characterization (size exclusion chromatography), in vitro endothelial cell signaling assay, prodomain release assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — protein biochemistry and functional reconstitution with purified human proteins; directly challenges prior mechanistic model","pmids":["31431534"],"is_preprint":false},{"year":2019,"finding":"Loss of BMP9 (genetic deletion or antibody neutralization) substantially protects against chronic hypoxia-induced pulmonary hypertension in mice. BMP9 affects the balance between endothelin-1, apelin, and adrenomedullin in pulmonary endothelial cells; Bmp9-/- mice show lower ET-1 and higher apelin/ADM mRNA. BMP9-mediated vasoconstriction is inhibited by the endothelin receptor antagonist bosentan.","method":"Bmp9-/- mouse model, neutralizing anti-BMP9 antibodies, ALK1ECD ligand trap in monocrotaline/SuHx rat models, right ventricular systolic pressure measurement, in vitro human pulmonary endothelial cells, chick chorioallantoic membrane assay","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus antibody neutralization plus pharmacological rescue in multiple animal models","pmids":["30636542"],"is_preprint":false},{"year":2019,"finding":"BMP9 mutations (missense) identified in IPAH patients impair BMP9 secretion and reduce anti-apoptotic activity in pulmonary arterial endothelial cells; patients with BMP9 mutations have lower plasma BMP9 levels.","method":"Exome sequencing, in vitro mutant protein expression, secretion assay, apoptosis assay in PAECs, plasma BMP9 ELISA","journal":"The European respiratory journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assays for secretion and anti-apoptosis, single study","pmids":["30578397"],"is_preprint":false},{"year":2020,"finding":"Crystal structures of BMP10:ALK1 complex (2.3 Å) and prodomain-bound BMP9:ALK1 complex (3.3 Å) reveal a tripartite recognition mechanism defining BMP9/BMP10 specificity for ALK1. Introduction of BMP10-specific residues into BMP9 yields ligands with diminished C2C12 signaling, validating the mechanism. Crossveinless 2 is predicted and experimentally confirmed not to inhibit BMP9.","method":"X-ray crystallography (2.3 Å and 3.3 Å), mutagenesis (BMP10 residues introduced into BMP9), C2C12 signaling assay, in vivo bone formation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures combined with mutagenesis and functional validation in vitro and in vivo","pmids":["32238803"],"is_preprint":false},{"year":2020,"finding":"GDF2 missense mutations found in PAH patients cause impaired BMP9 cellular processing and secretion; patients carrying these mutations have reduced plasma BMP9 levels and reduced BMP activity. Unexpectedly, plasma BMP10 levels are also markedly reduced in individuals with GDF2 mutations.","method":"In vitro mutant BMP9 protein expression, secretion assay, plasma ELISA for BMP9 and BMP10, endothelial Smad signaling bioassay","journal":"American journal of respiratory and critical care medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro protein processing and functional assays with patient plasma validation, single lab","pmids":["31661308"],"is_preprint":false},{"year":2020,"finding":"BMP9 and BMP10 act directly on vascular smooth muscle cells (VSMCs) via ALK1 to induce and maintain the contractile state; combined genetic inactivation of Bmp9 and Bmp10 causes decreased systemic blood pressure and diminished VSMC layer. ALK1 deletion in VSMCs recapitulates the Bmp9/10 phenotype in pulmonary but not aortic arteries, indicating vessel-bed specific receptor combinations.","method":"Cell-type specific conditional KO mouse models, blood pressure measurement, pulmonary VSMC isolation and phenotypic analysis, single molecule FISH, bulk RNA-seq, Smad7 VSMC-specific overexpression","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional transgenic mouse models with physiological readouts and transcriptomic analyses","pmids":["33334130"],"is_preprint":false},{"year":2020,"finding":"BMP9-induced ALK1 endocytosis in endothelial cells is mediated by caveolin-1 (CAV-1) and dynamin-2 (DNM2) but not clathrin; knockdown of CAV-1 reduces BMP9-mediated ALK1 internalization, BMP9-dependent Smad1/5 signaling and gene expression. BMP9 treatment strongly reduces LDL transcytosis via ALK1 internalization.","method":"Endothelial cell imaging, siRNA knockdown of CAV-1/DNM2/clathrin, SMAD1/5 phosphorylation western blot, LDL transcytosis assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple functional readouts (signaling and LDL transcytosis), single lab","pmids":["33097593"],"is_preprint":false},{"year":2020,"finding":"CRISPR-mediated BMP9 ablation in mice causes hepatosteatosis due to downregulated PPARα expression and reduced fatty acid oxidation; BMP9 activates PPARα promoter activity via p-Smad signaling. AAV-mediated BMP9 overexpression in mouse liver relieves liver steatosis.","method":"CRISPR BMP9 knockout mice, lipid accumulation assays, PPARα promoter activity assay, p-Smad western blot, PPARα antagonist GW6471, AAV-mediated overexpression","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO and AAV rescue with defined molecular mechanism (PPARα/p-Smad), multiple approaches","pmids":["33246954"],"is_preprint":false},{"year":2020,"finding":"BMP9 and BMP10 repress basal CCL2 expression and release from human pulmonary artery and aortic endothelial cells via ALK1, co-dependent on ACTR-IIA and BMPR-II, and requiring Smad4; Smad1/5 signaling contributes only at near-circulating BMP9 concentrations.","method":"siRNA knockdown of ALK1, ACTR-IIA, BMPR-II, Smad4; Smad1/5 inhibition; CCL2 ELISA; Smad signaling western blot","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic siRNA receptor dissection with functional CCL2 readout, single lab","pmids":["32576665"],"is_preprint":false},{"year":2021,"finding":"Endogenous circulating BMP9 is a pulmonary endothelial-protective factor that maintains vascular barrier function; BMP9 neutralization in mice increases lung vascular permeability, interstitial edema, and neutrophil extravasation. During LPS-induced lung injury, circulating BMP9 is markedly reduced due to decreased hepatic BMP9 mRNA and increased elastase activity. Exogenous BMP9 prevents LPS-induced lung injury.","method":"BMP9-neutralizing antibody in mice, lung vascular permeability assay, neutrophil extravasation measurement, murine acute lung injury (inhaled LPS) model, hepatic BMP9 mRNA quantification, plasma elastase activity, patient plasma BMP9 ELISA","journal":"American journal of respiratory and critical care medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic/antibody loss-of-function, in vivo rescue, and human patient validation in one study","pmids":["33320799"],"is_preprint":false},{"year":2021,"finding":"Homozygous GDF2 nonsense mutations result in undetectable plasma BMP9 and BMP10 levels, demonstrating that loss of circulating BMP9 also abolishes circulating BMP10; heterozygous carriers have reduced but functional BMP9/BMP10 levels. Alternate translation at Met57 in one nonsense mutant does not yield secreted functional BMP9.","method":"Plasma ELISA for BMP9 and BMP10, endothelial BRE-luciferase reporter serum bioassay, in vitro mutant protein expression and secretion assay","journal":"Molecular genetics & genomic medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient plasma assays combined with in vitro protein expression studies, single lab","pmids":["33834622"],"is_preprint":false},{"year":2021,"finding":"BMP9 reduces osteoblast senescence by activating Smad1, which suppresses STAT1 transcriptional activity and thereby inhibits P21 expression and SASP production; this Smad1-Stat1-P21 axis mediates BMP9's protection against age-related bone loss in aged mice.","method":"Aged mouse model, Smad1 signaling inhibition in vivo, Stat1 and P21 expression analysis, SASP markers, bone mass measurement","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo inhibition of pathway with molecular readouts, single lab","pmids":["35523787"],"is_preprint":false},{"year":2021,"finding":"BMP9-ID1 signaling promotes EpCAM-positive HCC cancer stem cell properties via enhancing Wnt/β-catenin signaling; ID1 knockdown represses BMP9-promoted HCC-CSC properties. BMP receptor inhibitors (K02288, LDN-212854) block BMP9-ID1 signaling and suppress HCC tumor growth in vivo.","method":"siRNA knockdown of ID1, BMP receptor inhibitor treatment, EpCAM/ID1 expression, in vivo HCC xenograft, Wnt/β-catenin signaling assay","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA, pharmacological inhibition, and in vivo model, single lab","pmids":["33834612"],"is_preprint":false},{"year":2022,"finding":"FOXF1 transcription factor activates BMP9/ACVRL1/SMAD1 signaling in pulmonary endothelial progenitor cells; FOXF1 synergizes with ETS transcription factor FLI1 to activate the ACVRL1 promoter. Nanoparticle-mediated ACVRL1 silencing in newborn mice decreases neonatal lung angiogenesis, and exogenous BMP9 restores angiogenesis in ACVRL1-deficient and Foxf1 mutant mice.","method":"scRNA-seq, Foxf1 mutant mice (ACDMPV model), ACVRL1 promoter activation assay, nanoparticle siRNA knockdown in neonatal mice, BMP9 rescue treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — transcriptomic pathway identification with genetic mouse models, nanoparticle silencing, and BMP9 rescue","pmids":["35440116"],"is_preprint":false},{"year":2022,"finding":"BMP10 is the critical physiological ligand for ENG-ALK1 arteriovenous network formation, while BMP9 has limited compensatory function; Bmp10-iKO mice develop AVMs while Bmp9-KO mice show no noticeable vascular defects. BMP10 protein (but not BMP9 protein) prevents retinal AVM in Bmp9/10-dKO and endothelial Eng-iKO mice.","method":"Conditional Bmp10-iKO and Bmp9/10-dKO mouse models, retinal vascular morphometry, brain/skin AVM analysis, BMP9 and BMP10 protein rescue injections","journal":"Angiogenesis","confidence":"High","confidence_rationale":"Tier 2 / Strong — comparative genetic models and protein rescue experiments directly dissecting BMP9 vs BMP10 contributions","pmids":["36348215"],"is_preprint":false},{"year":2024,"finding":"BMP9 and BMP10 activate a non-canonical transcriptional SMAD-dependent MAPK pathway (MEKK4/GADD45β/P38) in endothelial cells, which is required for expression of GADD45β; activated P38 phosphorylates HSP27 and Eps15, and regulates specific gene expression (E-selectin, hyaluronan synthase 2, COX-2). BMP10 induces G1 cell cycle arrest by modulating CDK4/6 pathway and inhibiting E2F2, cyclinD1, cyclinA1 mRNA expression.","method":"Large-scale phosphoproteomics, western blot validation of phosphosites, RT-qPCR, flow cytometry cell cycle analysis","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — unbiased phosphoproteomics with western blot and functional validation, single lab","pmids":["38439036"],"is_preprint":false},{"year":2021,"finding":"A heterozygous GDF2 variant causes HHT with pulmonary AVMs; in vitro, the mutant construct expresses the proprotein but lacks active mature BMP9 dimer, indicating the mutation disrupts correct protein cleavage. Plasma BMP9 levels in patients are significantly lower than controls.","method":"In vitro mutant BMP9 expression, protein processing/cleavage assay, plasma BMP9 ELISA","journal":"American journal of medical genetics. Part A","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro protein cleavage assay with patient plasma validation, single lab","pmids":["34904380"],"is_preprint":false}],"current_model":"GDF2/BMP9 is a liver-derived circulating homodimeric cytokine that signals by binding with high affinity to the type I receptor ALK1 (and to endoglin as a co-receptor) on vascular endothelial cells, engaging type II receptors BMPR-II and ActR-IIA to activate canonical Smad1/5/8 phosphorylation and non-canonical pathways including p38 MAPK (via GADD45β/MEKK4), maintaining endothelial quiescence, vascular barrier integrity, and smooth muscle contractility; in mesenchymal stem cells BMP9 signals through ALK1/ALK2 and Smad1/5/8 to potently drive osteogenic differentiation with cross-talk from Wnt/β-catenin, Notch, IGF/PI3K-AKT, and MAPK pathways; BMP9 activity is regulated by a redox-sensitive intermolecular disulfide bond affecting protease susceptibility, and by prodomain association that does not inhibit receptor binding; loss-of-function GDF2 mutations impair protein cleavage or secretion, reduce circulating BMP9 and BMP10, and cause pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, and vascular malformation syndromes."},"narrative":{"mechanistic_narrative":"GDF2/BMP9 is a liver-derived circulating homodimeric BMP-family cytokine that signals primarily through the type I receptor ALK1 (ACVRL1) with endoglin as co-receptor to maintain vascular endothelial quiescence and barrier function [PMID:17311849, PMID:22566602, PMID:28564608]. After secretion its pro-region remains tightly bound but does not block receptor engagement, and BMP9 binds ALK1 and endoglin with high affinity while engaging type II receptors BMPR-II and ActR-IIA to drive canonical Smad1/5/8 phosphorylation and ID1 induction [PMID:15851468, PMID:17311849, PMID:32576665]. Structural work defines a tripartite recognition mechanism conferring BMP9/BMP10 specificity for ALK1, shows that two endoglin copies embrace the BMP9 homodimer in a manner compatible with type I but not type II receptor binding, and reveals that activity and protease susceptibility are tuned by a redox-sensitive intermolecular disulfide bond [PMID:25237187, PMID:28564608, PMID:32238803]. In endothelium BMP9 enforces quiescence and limits angiogenesis through ID1, Notch (DLL4/Jagged1/Hey), and endoglin-dependent YAP1 programs, regulates the CXCL12/CXCR4 axis, controls retinal and lymphatic vascular remodeling and ductus arteriosus closure, and preserves vascular barrier integrity in part by repressing CCL2 and modulating endothelin-1/apelin balance [PMID:22566602, PMID:23018639, PMID:23741013, PMID:26056270, PMID:26471266, PMID:25909848, PMID:22299030, PMID:32576665, PMID:33320799]. Acting on vascular smooth muscle via ALK1, BMP9 and BMP10 induce and maintain the contractile state and set systemic blood pressure [PMID:33334130], and a non-canonical SMAD-dependent MEKK4/GADD45β/p38 MAPK arm controls additional endothelial gene expression and cell-cycle outputs [PMID:38439036]. In mesenchymal cells BMP9 potently drives osteogenic differentiation through Smad1/5/8 with cross-talk from IGF/PI3K-AKT and Notch signaling and protects against osteoblast senescence via a Smad1-STAT1-P21 axis [PMID:20499340, PMID:30353129, PMID:35523787], while in liver it is produced by hepatic stellate cells, promotes fibrosis via SMAD/ID1, and regulates lipid metabolism through PPARα [PMID:28336518, PMID:33246954]. Loss-of-function GDF2 mutations impair BMP9 cleavage or secretion, reduce circulating BMP9 and BMP10, and cause pulmonary arterial hypertension and hereditary hemorrhagic telangiectasia with vascular malformations [PMID:30578397, PMID:31661308, PMID:33834622, PMID:34904380]; conversely, BMP9 loss protects against chronic hypoxia-induced pulmonary hypertension, reflecting context-dependent roles [PMID:30636542].","teleology":[{"year":2005,"claim":"Establishing how BMP9 is structured and which receptor it uses defined the molecular starting point for all downstream signaling work.","evidence":"X-ray crystallography at 2.3 Å, SPR binding, and ligand-trap cell assays identifying ALK1 as a BMP9 receptor","pmids":["15851468"],"confidence":"High","gaps":["Did not resolve the receptor stoichiometry or type II receptor identity","Pro-region's physiological role left undefined"]},{"year":2007,"claim":"Defining the endothelial receptor repertoire and functional output showed BMP9 acts as an anti-angiogenic, quiescence-promoting ligand.","evidence":"Receptor-binding in COS cells plus Smad1/5, ID1, and endothelial proliferation/migration and in vivo angiogenesis assays","pmids":["17311849"],"confidence":"High","gaps":["Downstream transcriptional program incompletely mapped","In vivo vascular requirement not yet genetically tested"]},{"year":2010,"claim":"Cross-talk inputs to BMP9 osteogenic signaling were identified, showing IGF-2/PI3K-AKT potentiates Smad nuclear translocation.","evidence":"ALP, Smad reporter, immunofluorescence, PI3K inhibition, and ectopic bone formation in MSCs; separate work in cholinergic neurons via ALK1","pmids":["20499340","20554873"],"confidence":"Medium","gaps":["Single-lab mechanistic dissection","Direct biochemical link between AKT and Smad complex not defined"]},{"year":2012,"claim":"Genetic and antibody loss-of-function established BMP9 as an in vivo regulator of vascular remodeling and the CXCL12/CXCR4 axis.","evidence":"Bmp9-KO and neutralizing antibody in mice, retinal morphometry, microarray/MS, endoglin/ALK1 siRNA, hindlimb ischemia","pmids":["22566602","23018639"],"confidence":"High","gaps":["Apelin/Notch regulation mechanism not fully resolved","Endoglin-dependence detail single lab"]},{"year":2013,"claim":"BMP9's roles expanded to lymphatic maturation and hepatocellular autocrine survival signaling, broadening its functional scope.","evidence":"Bmp9-KO lymphatic morphometry and LEC assays; siRNA and ligand-trap proliferation/apoptosis assays in HepG2","pmids":["23741013","23936038"],"confidence":"High","gaps":["Tumor relevance of HepG2 autocrine signaling not validated in vivo","Valve gene regulation mechanism not detailed"]},{"year":2014,"claim":"The redox-controlled disulfide isoform and receptor/Smad requirements for VSMC and granulosa responses clarified how BMP9 activity is tuned and transduced.","evidence":"1.9 Å crystal structure and redox/protease assays; ALK1/Smad4 siRNA in VSMC calcification; ALK1/BMPR-II in granulosa cells","pmids":["25237187","25297851","25527306"],"confidence":"High","gaps":["Physiological enzyme controlling the redox switch not identified","VSMC calcification relevance in vivo not established"]},{"year":2015,"claim":"Mechanistic integration of BMP9 with Notch, YAP1/endoglin, and EPC differentiation programs revealed how quiescence and neovascularization outputs are coordinated, alongside a tumor-suppressive role in epithelial cells.","evidence":"Notch and ALK1-Smad inhibitor combinations, endoglin siRNA with zyxin/YAP1 imaging, EPC differentiation with ALK1 blockade, receptor co-IP and anoikis assays","pmids":["26471266","25909848","26229139","26678910"],"confidence":"Medium","gaps":["Pathway interdependence largely single-lab pharmacology","ALK3/ALK6 usage in epithelium contrasts with endothelial ALK1 and is not reconciled"]},{"year":2015,"claim":"BMP9 and BMP10 were shown to cooperatively drive ductus arteriosus closure via endothelial-to-mesenchymal differentiation.","evidence":"Bmp9-KO with anti-BMP10 neutralization, TEM, immunofluorescence, gene expression","pmids":["26056270"],"confidence":"High","gaps":["Specific ECM/differentiation genes mediating closure not pinpointed"]},{"year":2017,"claim":"The endoglin:BMP9 crystal structure mapped a disease-relevant binding interface and clarified that endoglin engagement is compatible only with type I receptor binding.","evidence":"X-ray crystallography of ENG ectodomain and ENG:BMP9 complex; non-canonical Smad1/p38 ET-1 release in PAECs; HSC-derived BMP9 driving liver fibrosis","pmids":["28564608","22299030","28336518"],"confidence":"High","gaps":["How endoglin presents BMP9 to type II receptors mechanistically unresolved","Source of circulating vs local BMP9 contributions not fully separated"]},{"year":2018,"claim":"BMP9/ALK1 was established as a barrier-protective signal in diabetic vasculature and a Notch-dependent osteogenic driver.","evidence":"Hyperglycemic endothelial model, STZ diabetic and Alk1 haploinsufficient mice, AAV BMP9 delivery; Notch inhibitor and dominant-negative Notch1 in MSC osteogenesis","pmids":["29880487","30353129"],"confidence":"Medium","gaps":["VE-cadherin/occludin regulation mechanism single lab","Notch intermediate-stage requirement not biochemically defined"]},{"year":2019,"claim":"Patient genetics and protein biochemistry linked GDF2 loss-of-function to pulmonary hypertension while redefining soluble endoglin as a signaling partner rather than an inhibitory trap; paradoxically, BMP9 loss protected against hypoxic PH.","evidence":"Exome sequencing with secretion/apoptosis assays in PAECs; purified sENG:BMP9 reconstitution; Bmp9-KO/antibody/ALK1ECD across multiple PH models","pmids":["30578397","31431534","30636542"],"confidence":"High","gaps":["Protective vs causative roles of BMP9 in PH not mechanistically reconciled","sENG complex physiological abundance unclear"]},{"year":2020,"claim":"Structural specificity, receptor internalization, VSMC contractility control, hepatic metabolism, and the BMP9/BMP10 interdependence in mutation carriers were defined, yielding a systems-level view.","evidence":"BMP9/BMP10:ALK1 crystal structures with mutagenesis; CAV-1/DNM2 endocytosis and LDL transcytosis assays; conditional Bmp9/Bmp10 and VSMC-Alk1 KO with blood pressure; CRISPR BMP9-KO hepatosteatosis with PPARα; CCL2 receptor dissection; GDF2 mutation plasma BMP9/BMP10 ELISA","pmids":["32238803","33097593","33334130","33246954","32576665","31661308"],"confidence":"High","gaps":["Vessel-bed-specific receptor combinations only partially mapped","Mechanism coupling BMP9 loss to BMP10 reduction unresolved"]},{"year":2021,"claim":"Circulating BMP9 was confirmed as a barrier-protective factor in lung injury, with mutation studies and FOXF1 transcriptional control further defining its production and downstream programs, plus roles in osteoblast senescence and HCC stemness.","evidence":"Anti-BMP9 antibody and LPS lung injury with patient plasma; nonsense-mutation plasma ELISA/bioassay; FOXF1/FLI1 ACVRL1 promoter and neonatal lung models; Smad1-STAT1-P21 in aged mice; BMP9-ID1 Wnt in HCC","pmids":["33320799","33834622","35440116","35523787","33834612","34904380"],"confidence":"High","gaps":["Hepatic regulation of BMP9 during injury incompletely characterized","FOXF1-BMP9 axis specificity beyond lung not tested"]},{"year":2022,"claim":"Comparative genetics dissected BMP9 from BMP10, showing BMP10 is the dominant physiological ENG-ALK1 ligand for arteriovenous network formation.","evidence":"Conditional Bmp10-iKO, Bmp9/10-dKO, and Eng-iKO mice with retinal/AVM morphometry and protein rescue","pmids":["36348215"],"confidence":"High","gaps":["Why GDF2 mutations cause HHT despite limited BMP9 vascular requirement not reconciled"]},{"year":2024,"claim":"A non-canonical SMAD-dependent MEKK4/GADD45β/p38 MAPK arm was defined, expanding BMP9/BMP10 signaling beyond canonical Smad transcription.","evidence":"Phosphoproteomics with western blot validation, RT-qPCR, and cell-cycle flow cytometry in endothelial cells","pmids":["38439036"],"confidence":"Medium","gaps":["In vivo relevance of the p38 arm not established","Single-lab phosphoproteomic dataset"]},{"year":null,"claim":"The molecular basis for the coupled loss of circulating BMP10 when GDF2/BMP9 is mutated, and the reconciliation of BMP9's protective versus pathogenic roles across vascular beds, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No mechanism linking BMP9 loss to reduced BMP10 stability/secretion","Vessel-bed-specific protective vs harmful BMP9 effects not unified","Therapeutic targeting window in PAH/HHT undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,16,24]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,8,17,29]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,22,30]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,18,30,31]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,8,36]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,7,11,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[22,23,25,37]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[26,30]}],"complexes":[],"partners":["ACVRL1","ENG","BMPR2","ACVR2A","BMP10","ACVR1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UK05","full_name":"Growth/differentiation factor 2","aliases":["Bone morphogenetic protein 9","BMP-9"],"length_aa":429,"mass_kda":47.3,"function":"Potent circulating inhibitor of angiogenesis. Signals through the type I activin receptor ACVRL1 but not other Alks. Signaling through SMAD1 in endothelial cells requires TGF-beta coreceptor endoglin/ENG","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9UK05/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GDF2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GDF2","total_profiled":1310},"omim":[{"mim_id":"620997","title":"SEMAPHORIN 3G; SEMA3G","url":"https://www.omim.org/entry/620997"},{"mim_id":"616334","title":"TRANSMEMBRANE PROTEIN 100; TMEM100","url":"https://www.omim.org/entry/616334"},{"mim_id":"615506","title":"TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5","url":"https://www.omim.org/entry/615506"},{"mim_id":"608748","title":"BONE MORPHOGENETIC PROTEIN 10; BMP10","url":"https://www.omim.org/entry/608748"},{"mim_id":"606522","title":"GROWTH/DIFFERENTIATION FACTOR 3; GDF3","url":"https://www.omim.org/entry/606522"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"liver","ntpm":17.4}],"url":"https://www.proteinatlas.org/search/GDF2"},"hgnc":{"alias_symbol":["BMP-9","BMP9"],"prev_symbol":[]},"alphafold":{"accession":"Q9UK05","domains":[{"cath_id":"2.60.120,2.60.120","chopping":"112-178_190-260","consensus_level":"high","plddt":86.6696,"start":112,"end":260},{"cath_id":"2.10.90.10","chopping":"263-281_324-429","consensus_level":"medium","plddt":88.5239,"start":263,"end":429}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UK05","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UK05-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UK05-F1-predicted_aligned_error_v6.png","plddt_mean":74.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GDF2","jax_strain_url":"https://www.jax.org/strain/search?query=GDF2"},"sequence":{"accession":"Q9UK05","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UK05.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UK05/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UK05"}},"corpus_meta":[{"pmid":"17311849","id":"PMC_17311849","title":"BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17311849","citation_count":441,"is_preprint":false},{"pmid":"15851468","id":"PMC_15851468","title":"Crystal structure of BMP-9 and functional interactions with pro-region and receptors.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15851468","citation_count":244,"is_preprint":false},{"pmid":"20499340","id":"PMC_20499340","title":"Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/20499340","citation_count":230,"is_preprint":false},{"pmid":"11748585","id":"PMC_11748585","title":"BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1.","date":"2001","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11748585","citation_count":214,"is_preprint":false},{"pmid":"22566602","id":"PMC_22566602","title":"BMP9 and BMP10 are critical for postnatal retinal vascular remodeling.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22566602","citation_count":205,"is_preprint":false},{"pmid":"23671813","id":"PMC_23671813","title":"BMP9 signaling in stem cell differentiation and osteogenesis.","date":"2013","source":"American journal of stem cells","url":"https://pubmed.ncbi.nlm.nih.gov/23671813","citation_count":160,"is_preprint":false},{"pmid":"20406889","id":"PMC_20406889","title":"BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo.","date":"2010","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/20406889","citation_count":143,"is_preprint":false},{"pmid":"21453282","id":"PMC_21453282","title":"BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential.","date":"2011","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21453282","citation_count":142,"is_preprint":false},{"pmid":"28336518","id":"PMC_28336518","title":"BMP-9 interferes with liver regeneration and promotes liver fibrosis.","date":"2017","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/28336518","citation_count":131,"is_preprint":false},{"pmid":"28564608","id":"PMC_28564608","title":"Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28564608","citation_count":123,"is_preprint":false},{"pmid":"23741013","id":"PMC_23741013","title":"Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23741013","citation_count":117,"is_preprint":false},{"pmid":"30578397","id":"PMC_30578397","title":"Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension.","date":"2019","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/30578397","citation_count":116,"is_preprint":false},{"pmid":"30636542","id":"PMC_30636542","title":"Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension.","date":"2019","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/30636542","citation_count":107,"is_preprint":false},{"pmid":"31661308","id":"PMC_31661308","title":"Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension.","date":"2020","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31661308","citation_count":103,"is_preprint":false},{"pmid":"25620979","id":"PMC_25620979","title":"Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.","date":"2015","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25620979","citation_count":98,"is_preprint":false},{"pmid":"32042861","id":"PMC_32042861","title":"The wonders of BMP9: From mesenchymal stem cell differentiation, angiogenesis, neurogenesis, tumorigenesis, and metabolism to regenerative medicine.","date":"2019","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32042861","citation_count":96,"is_preprint":false},{"pmid":"31431534","id":"PMC_31431534","title":"Role of soluble endoglin in BMP9 signaling.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31431534","citation_count":69,"is_preprint":false},{"pmid":"23018639","id":"PMC_23018639","title":"BMP9 regulates endoglin-dependent chemokine responses in endothelial cells.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23018639","citation_count":69,"is_preprint":false},{"pmid":"32238803","id":"PMC_32238803","title":"Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32238803","citation_count":68,"is_preprint":false},{"pmid":"23936038","id":"PMC_23936038","title":"BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23936038","citation_count":64,"is_preprint":false},{"pmid":"30353129","id":"PMC_30353129","title":"BMP9-induced osteoblastic differentiation requires functional Notch signaling in mesenchymal stem cells.","date":"2018","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30353129","citation_count":64,"is_preprint":false},{"pmid":"33334130","id":"PMC_33334130","title":"BMP9 and BMP10 Act Directly on Vascular Smooth Muscle Cells for Generation and Maintenance of the Contractile State.","date":"2020","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/33334130","citation_count":63,"is_preprint":false},{"pmid":"34240497","id":"PMC_34240497","title":"BMP9 and BMP10: Two close vascular quiescence partners that stand out.","date":"2021","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/34240497","citation_count":62,"is_preprint":false},{"pmid":"25297851","id":"PMC_25297851","title":"BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth muscle cells through an ALK1 mediated pathway.","date":"2014","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25297851","citation_count":62,"is_preprint":false},{"pmid":"34086873","id":"PMC_34086873","title":"Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/34086873","citation_count":60,"is_preprint":false},{"pmid":"33320799","id":"PMC_33320799","title":"Circulating BMP9 Protects the Pulmonary Endothelium during Inflammation-induced Lung Injury in Mice.","date":"2021","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33320799","citation_count":56,"is_preprint":false},{"pmid":"27081547","id":"PMC_27081547","title":"Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia.","date":"2015","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/27081547","citation_count":55,"is_preprint":false},{"pmid":"26471266","id":"PMC_26471266","title":"DLL4/Notch1 and BMP9 Interdependent Signaling Induces Human Endothelial Cell Quiescence via P27KIP1 and Thrombospondin-1.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26471266","citation_count":55,"is_preprint":false},{"pmid":"11426468","id":"PMC_11426468","title":"Morphologic analysis of BMP-9 gene therapy-induced osteogenesis.","date":"2001","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/11426468","citation_count":54,"is_preprint":false},{"pmid":"26056270","id":"PMC_26056270","title":"BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26056270","citation_count":54,"is_preprint":false},{"pmid":"24805814","id":"PMC_24805814","title":"BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24805814","citation_count":54,"is_preprint":false},{"pmid":"23981660","id":"PMC_23981660","title":"BMP9 and COX-2 form an important regulatory loop in BMP9-induced osteogenic differentiation of mesenchymal stem cells.","date":"2013","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/23981660","citation_count":53,"is_preprint":false},{"pmid":"35440116","id":"PMC_35440116","title":"Endothelial progenitor cells stimulate neonatal lung angiogenesis through FOXF1-mediated activation of BMP9/ACVRL1 signaling.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35440116","citation_count":52,"is_preprint":false},{"pmid":"24670474","id":"PMC_24670474","title":"Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24670474","citation_count":50,"is_preprint":false},{"pmid":"24439409","id":"PMC_24439409","title":"BMP-9 as a potent brown adipogenic inducer with anti-obesity capacity.","date":"2014","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/24439409","citation_count":50,"is_preprint":false},{"pmid":"21892652","id":"PMC_21892652","title":"BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231.","date":"2011","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21892652","citation_count":50,"is_preprint":false},{"pmid":"34904380","id":"PMC_34904380","title":"Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34904380","citation_count":49,"is_preprint":false},{"pmid":"33545890","id":"PMC_33545890","title":"Osteogenic differentiation cues of the bone morphogenetic protein-9 (BMP-9) and its recent advances in bone tissue regeneration.","date":"2020","source":"Materials science & engineering. C, Materials for biological applications","url":"https://pubmed.ncbi.nlm.nih.gov/33545890","citation_count":48,"is_preprint":false},{"pmid":"27528761","id":"PMC_27528761","title":"Regulation of the ALK1 ligands, BMP9 and BMP10.","date":"2016","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/27528761","citation_count":47,"is_preprint":false},{"pmid":"29880487","id":"PMC_29880487","title":"BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability.","date":"2018","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29880487","citation_count":47,"is_preprint":false},{"pmid":"28214873","id":"PMC_28214873","title":"NEL-Like Molecule-1 (Nell1) Is Regulated by Bone Morphogenetic Protein 9 (BMP9) and Potentiates BMP9-Induced Osteogenic Differentiation at the Expense of Adipogenesis in Mesenchymal Stem Cells.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28214873","citation_count":47,"is_preprint":false},{"pmid":"32454407","id":"PMC_32454407","title":"Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32454407","citation_count":47,"is_preprint":false},{"pmid":"27725853","id":"PMC_27725853","title":"Bone morphogenetic protein 9 (BMP9) induces effective bone formation from reversibly immortalized multipotent adipose-derived (iMAD) mesenchymal stem cells.","date":"2016","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/27725853","citation_count":47,"is_preprint":false},{"pmid":"33080042","id":"PMC_33080042","title":"Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats.","date":"2020","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33080042","citation_count":46,"is_preprint":false},{"pmid":"22299030","id":"PMC_22299030","title":"BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22299030","citation_count":45,"is_preprint":false},{"pmid":"32041483","id":"PMC_32041483","title":"Leptin Potentiates BMP9-Induced Osteogenic Differentiation of Mesenchymal Stem Cells Through the Activation of JAK/STAT Signaling.","date":"2020","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/32041483","citation_count":43,"is_preprint":false},{"pmid":"31914211","id":"PMC_31914211","title":"BMP9 Reduces Bone Loss in Ovariectomized Mice by Dual Regulation of Bone Remodeling.","date":"2020","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/31914211","citation_count":43,"is_preprint":false},{"pmid":"25237187","id":"PMC_25237187","title":"Regulation of bone morphogenetic protein 9 (BMP9) by redox-dependent proteolysis.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25237187","citation_count":41,"is_preprint":false},{"pmid":"29223735","id":"PMC_29223735","title":"Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29223735","citation_count":41,"is_preprint":false},{"pmid":"26794904","id":"PMC_26794904","title":"LPS-stimulated inflammation inhibits BMP-9-induced osteoblastic differentiation through crosstalk between BMP/MAPK and Smad signaling.","date":"2016","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26794904","citation_count":39,"is_preprint":false},{"pmid":"20554873","id":"PMC_20554873","title":"BMP9 (bone morphogenetic protein 9) induces NGF as an autocrine/paracrine cholinergic trophic factor in developing basal forebrain neurons.","date":"2010","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20554873","citation_count":39,"is_preprint":false},{"pmid":"30816068","id":"PMC_30816068","title":"Dentinogenesis and Tooth-Alveolar Bone Complex Defects in BMP9/GDF2 Knockout Mice.","date":"2019","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/30816068","citation_count":38,"is_preprint":false},{"pmid":"25393508","id":"PMC_25393508","title":"Potential roles of BMP9 in liver fibrosis.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25393508","citation_count":38,"is_preprint":false},{"pmid":"33246954","id":"PMC_33246954","title":"CRISPR-mediated BMP9 ablation promotes liver steatosis via the down-regulation of PPARα expression.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33246954","citation_count":38,"is_preprint":false},{"pmid":"35163396","id":"PMC_35163396","title":"BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163396","citation_count":35,"is_preprint":false},{"pmid":"33834622","id":"PMC_33834622","title":"Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an \"HHT-like\" syndrome in children.","date":"2021","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33834622","citation_count":35,"is_preprint":false},{"pmid":"25909848","id":"PMC_25909848","title":"BMP9 Crosstalk with the Hippo Pathway Regulates Endothelial Cell Matricellular and Chemokine Responses.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25909848","citation_count":35,"is_preprint":false},{"pmid":"32042114","id":"PMC_32042114","title":"BMP9 signaling promotes the normalization of tumor blood vessels.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32042114","citation_count":32,"is_preprint":false},{"pmid":"29977042","id":"PMC_29977042","title":"BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29977042","citation_count":31,"is_preprint":false},{"pmid":"29909342","id":"PMC_29909342","title":"FAK and BMP-9 synergistically trigger osteogenic differentiation and bone formation of adipose derived stem cells through enhancing Wnt-β-catenin signaling.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29909342","citation_count":31,"is_preprint":false},{"pmid":"26229139","id":"PMC_26229139","title":"BMP9 Induces Cord Blood-Derived Endothelial Progenitor Cell Differentiation and Ischemic Neovascularization via ALK1.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26229139","citation_count":31,"is_preprint":false},{"pmid":"29642505","id":"PMC_29642505","title":"BMP9 Promotes the Proliferation and Migration of Bladder Cancer Cells through Up-Regulating lncRNA UCA1.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29642505","citation_count":31,"is_preprint":false},{"pmid":"32215293","id":"PMC_32215293","title":"Highly expressed BMP9/GDF2 in postnatal mouse liver and lungs may account for its pleiotropic effects on stem cell differentiation, angiogenesis, tumor growth and metabolism.","date":"2019","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32215293","citation_count":30,"is_preprint":false},{"pmid":"33097593","id":"PMC_33097593","title":"BMP-9 and LDL crosstalk regulates ALK-1 endocytosis and LDL transcytosis in endothelial cells.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33097593","citation_count":28,"is_preprint":false},{"pmid":"27477105","id":"PMC_27477105","title":"Effects of BMP-9 and BMP-2 on the PI3K/Akt Pathway in MC3T3-E1 Preosteoblasts.","date":"2016","source":"Tissue engineering. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/27477105","citation_count":28,"is_preprint":false},{"pmid":"36348215","id":"PMC_36348215","title":"BMP10 functions independently from BMP9 for the development of a proper arteriovenous network.","date":"2022","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/36348215","citation_count":28,"is_preprint":false},{"pmid":"33245175","id":"PMC_33245175","title":"CHRDL2 promotes osteosarcoma cell proliferation and metastasis through the BMP-9/PI3K/AKT pathway.","date":"2021","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/33245175","citation_count":27,"is_preprint":false},{"pmid":"31240956","id":"PMC_31240956","title":"FAK mediates BMP9-induced osteogenic differentiation via Wnt and MAPK signaling pathway in synovial mesenchymal stem cells.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31240956","citation_count":27,"is_preprint":false},{"pmid":"33834612","id":"PMC_33834612","title":"BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33834612","citation_count":25,"is_preprint":false},{"pmid":"26678910","id":"PMC_26678910","title":"Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia.","date":"2015","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/26678910","citation_count":24,"is_preprint":false},{"pmid":"32576665","id":"PMC_32576665","title":"Endothelial protective factors BMP9 and BMP10 inhibit CCL2 release by human vascular endothelial cells.","date":"2020","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/32576665","citation_count":24,"is_preprint":false},{"pmid":"38626313","id":"PMC_38626313","title":"Disrupted BMP-9 Signaling Impairs Pulmonary Vascular Integrity in Hepatopulmonary Syndrome.","date":"2024","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38626313","citation_count":23,"is_preprint":false},{"pmid":"25527306","id":"PMC_25527306","title":"Regulatory role of BMP-9 in steroidogenesis by rat ovarian granulosa cells.","date":"2014","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25527306","citation_count":23,"is_preprint":false},{"pmid":"26343646","id":"PMC_26343646","title":"BMP9-Induced Survival Effect in Liver Tumor Cells Requires p38MAPK Activation.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26343646","citation_count":23,"is_preprint":false},{"pmid":"32574673","id":"PMC_32574673","title":"New insights into BMP9 signaling in organ fibrosis.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32574673","citation_count":22,"is_preprint":false},{"pmid":"27085971","id":"PMC_27085971","title":"BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/27085971","citation_count":22,"is_preprint":false},{"pmid":"27208502","id":"PMC_27208502","title":"Identification of bone morphogenetic protein 9 (BMP9) as a novel profibrotic factor in vitro.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27208502","citation_count":22,"is_preprint":false},{"pmid":"26214439","id":"PMC_26214439","title":"Synergistic effect of BMP9 and TGF-β in the proliferation and differentiation of osteoblasts.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26214439","citation_count":21,"is_preprint":false},{"pmid":"32143367","id":"PMC_32143367","title":"BMP-9 Modulates the Hepatic Responses to LPS.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32143367","citation_count":20,"is_preprint":false},{"pmid":"35523787","id":"PMC_35523787","title":"BMP9 reduces age-related bone loss in mice by inhibiting osteoblast senescence through Smad1-Stat1-P21 axis.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35523787","citation_count":20,"is_preprint":false},{"pmid":"32669404","id":"PMC_32669404","title":"Homozygous GDF2-Related Hereditary Hemorrhagic Telangiectasia in a Chinese Family.","date":"2020","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/32669404","citation_count":19,"is_preprint":false},{"pmid":"32510140","id":"PMC_32510140","title":"BMP9 is a potential therapeutic agent for use in oral and maxillofacial bone tissue engineering.","date":"2020","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/32510140","citation_count":19,"is_preprint":false},{"pmid":"31127068","id":"PMC_31127068","title":"Advances in the molecular regulation of endothelial BMP9 signalling complexes and implications for cardiovascular disease.","date":"2019","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/31127068","citation_count":19,"is_preprint":false},{"pmid":"35923297","id":"PMC_35923297","title":"Resveratrol Synergistically Promotes BMP9-Induced Osteogenic Differentiation of Mesenchymal Stem Cells.","date":"2022","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/35923297","citation_count":19,"is_preprint":false},{"pmid":"34611981","id":"PMC_34611981","title":"Clinical manifestations of patients with GDF2 mutations associated with hereditary hemorrhagic telangiectasia type 5.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34611981","citation_count":19,"is_preprint":false},{"pmid":"32478395","id":"PMC_32478395","title":"BMP9 exhibits dual and coupled roles in inducing osteogenic and angiogenic differentiation of mesenchymal stem cells.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32478395","citation_count":18,"is_preprint":false},{"pmid":"31680322","id":"PMC_31680322","title":"BMP9 promotes osteogenic differentiation of SMSCs by activating the JNK/Smad2/3 signaling pathway.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31680322","citation_count":18,"is_preprint":false},{"pmid":"34771575","id":"PMC_34771575","title":"The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34771575","citation_count":17,"is_preprint":false},{"pmid":"32730768","id":"PMC_32730768","title":"BMP9 attenuates occurrence of venous malformation by maintaining endothelial quiescence and strengthening vessel walls via SMAD1/5/ID1/α-SMA pathway.","date":"2020","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32730768","citation_count":17,"is_preprint":false},{"pmid":"28228716","id":"PMC_28228716","title":"Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28228716","citation_count":17,"is_preprint":false},{"pmid":"38294582","id":"PMC_38294582","title":"Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors.","date":"2024","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38294582","citation_count":16,"is_preprint":false},{"pmid":"20102315","id":"PMC_20102315","title":"Effect of BMP-9 and its derived peptide on the differentiation of human white preadipocytes.","date":"2010","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/20102315","citation_count":16,"is_preprint":false},{"pmid":"33461171","id":"PMC_33461171","title":"Long non-coding RNA (LncRNA) HOTAIR regulates BMP9-induced osteogenic differentiation by targeting the proliferation of mesenchymal stem cells (MSCs).","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33461171","citation_count":16,"is_preprint":false},{"pmid":"35985370","id":"PMC_35985370","title":"The SIRT1 activator SRT2104 promotes BMP9-induced osteogenic and angiogenic differentiation in mesenchymal stem cells.","date":"2022","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/35985370","citation_count":15,"is_preprint":false},{"pmid":"34265413","id":"PMC_34265413","title":"BMP-9 downregulates StAR expression and progesterone production by activating both SMAD1/5/8 and SMAD2/3 signaling pathways in human granulosa-lutein cells obtained from gonadotropins induced ovarian cycles.","date":"2021","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/34265413","citation_count":15,"is_preprint":false},{"pmid":"34150011","id":"PMC_34150011","title":"A functional autophagy pathway is essential for BMP9-induced osteogenic differentiation of mesenchymal stem cells (MSCs).","date":"2021","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/34150011","citation_count":15,"is_preprint":false},{"pmid":"34019202","id":"PMC_34019202","title":"New insights into BMP9 signaling in liver diseases.","date":"2021","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34019202","citation_count":14,"is_preprint":false},{"pmid":"37894931","id":"PMC_37894931","title":"BMP-9 Improves the Osteogenic Differentiation Ability over BMP-2 through p53 Signaling In Vitro in Human Periosteum-Derived Cells.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37894931","citation_count":14,"is_preprint":false},{"pmid":"27056281","id":"PMC_27056281","title":"BMP-9 dependent pathways required for the chondrogenic differentiation of pluripotent stem cells.","date":"2016","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/27056281","citation_count":14,"is_preprint":false},{"pmid":"38439036","id":"PMC_38439036","title":"Large-scale phosphoproteomics reveals activation of the MAPK/GADD45β/P38 axis and cell cycle inhibition in response to BMP9 and BMP10 stimulation in endothelial cells.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38439036","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54176,"output_tokens":9839,"usd":0.155057,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20142,"output_tokens":5367,"usd":0.117443,"stage2_stop_reason":"end_turn"},"total_usd":0.2725,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"BMP9 (GDF2) crystal structure resolved to 2.3 Å; the pro-region remains tightly associated with BMP9 after secretion but does not inhibit receptor binding or biological activity in cell-based assays. ALK1 identified as a receptor for BMP9 by surface plasmon resonance (BIAcore) and functional neutralization with soluble ALK1.\",\n      \"method\": \"X-ray crystallography (2.3 Å), surface plasmon resonance (BIAcore), cell-based activity assays with soluble ALK1 as ligand trap\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with SPR binding assays and functional cell-based assays in a single rigorous study\",\n      \"pmids\": [\"15851468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BMP9 binds with high affinity to ALK1 and endoglin, and weakly to ALK2 and BMPR-II/ActR-II in transfected COS cells; in endothelial cells BMP9 signals predominantly via ALK1 and BMPR-II, activating Smad1/5 and inducing ID1 protein and endoglin mRNA. BMP9 inhibits bFGF-stimulated endothelial cell proliferation/migration and blocks VEGF-induced angiogenesis.\",\n      \"method\": \"Receptor-binding assays in transfected COS cells, western blot (Smad1/5 phosphorylation), qRT-PCR, endothelial cell proliferation/migration assays, in vivo angiogenesis assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (binding, signaling, functional), replicated across labs\",\n      \"pmids\": [\"17311849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BMP9 induces NGF expression selectively in cholinergic (Chat-positive/p75-positive) basal forebrain neurons via ALK1; secreted NGF acts in an autocrine/paracrine manner to support acetylcholine production and ChAT gene expression. BMP9-induced Ngf expression requires new protein synthesis and is blocked by BMP type I receptor inhibition.\",\n      \"method\": \"Primary embryonic septal cell culture, FACS isolation of cholinergic neurons (GFP/p75), RT-PCR, pharmacological inhibition of BMP type I receptors, NGF ELISA\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FACS-based cell sorting with functional assays in one lab, single study\",\n      \"pmids\": [\"20554873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IGF-2 potentiates BMP9-induced osteogenic differentiation of mesenchymal stem cells by enhancing BMPR-Smad reporter activity and Smad1/5/8 nuclear translocation via PI3K/AKT signaling; PI3K inhibitor LY294002 abolishes this cross-talk and directly inhibits BMP9 activity.\",\n      \"method\": \"Alkaline phosphatase activity assay, Smad reporter assays, Smad1/5/8 nuclear translocation (immunofluorescence), pharmacological PI3K inhibition, ectopic bone formation in vivo\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays (reporter, nuclear translocation, in vivo bone formation), single lab\",\n      \"pmids\": [\"20499340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BMP9 is required for postnatal retinal vascular remodeling; neutralizing anti-BMP9 antibody increases retinal vascular density. BMP9 promotes endothelial quiescence and upregulates Notch pathway genes (Jagged1, Dll4, Hey1, Hey2, Hes1) while decreasing apelin expression in endothelial cells.\",\n      \"method\": \"Neutralizing antibody treatment in neonatal mice, Bmp9-KO mice, retinal vascular morphometry, gene expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and antibody neutralization in vivo with molecular pathway validation, replicated findings\",\n      \"pmids\": [\"22566602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BMP9 regulates the CXCL12/SDF1-CXCR4 chemokine axis in endothelial cells in an endoglin- and ALK1-dependent manner; RNA knockdown of endoglin or ALK1 impairs SDF1/CXCR4 regulation by BMP9 and impairs SDF1 expression in vivo in endoglin-deficient mice.\",\n      \"method\": \"cDNA microarray, quantitative mass spectrometry, siRNA knockdown of endoglin and ALK1, hindlimb ischemia mouse model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (transcriptomics, proteomics, siRNA, in vivo), single lab\",\n      \"pmids\": [\"23018639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BMP9 promotes proliferation and survival (anti-apoptotic function) in HepG2 hepatocellular carcinoma cells via autocrine signaling, activating Smad1/5/8 phosphorylation and Id1 upregulation; BMP9 also triggers cell cycle progression in these cells.\",\n      \"method\": \"siRNA knockdown, chemical inhibitors (ligand trap), proliferation assays, apoptosis assays (low-serum), Smad1/5/8 phosphorylation western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA, chemical inhibitors and functional assays, single lab\",\n      \"pmids\": [\"23936038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BMP9 controls lymphatic vessel maturation and valve formation via ALK1; Bmp9-KO mice show hyperplastic mesenteric collecting vessels retaining LYVE-1 expression, and BMP9 inhibits LYVE-1 expression in lymphatic endothelial cells in an ALK1-dependent manner. BMP9 upregulates valve formation genes (Foxc2, Connexin37, EphrinB2, Neuropilin1) in LECs.\",\n      \"method\": \"Bmp9-KO mice, lymphatic vessel morphometry, in vitro LEC treatment with BMP9, ALK1 dependency confirmed by inhibition, lymphatic drainage assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with in vitro mechanistic studies and lymphatic function assay\",\n      \"pmids\": [\"23741013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BMP9 induces VSMC osteogenic differentiation and calcification via ALK1 and Smad-dependent pathways; BMP9 activates Smad1/5/8 and Smad2/3 phosphorylation, both of which bind Smad4 to activate target genes. Smad4 siRNA knockdown significantly reduces BMP9-induced ALP activity and calcium deposition.\",\n      \"method\": \"In vitro VSMC calcification assay, soluble ALK1 chimeric protein inhibition, Smad siRNA, ALP inhibitor, western blot for Smad phosphorylation\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and siRNA-based mechanistic dissection, single lab, multiple readouts\",\n      \"pmids\": [\"25297851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BMP9 stability and activity are regulated by a redox-dependent mechanism: BMP9 dimers form with (D-form, disulfide-bonded) or without (M-form) an intermolecular disulfide bond, resolved by a 1.9 Å crystal structure. The M-form shows less sustained Smad1/5/8 phosphorylation and greater susceptibility to redox-dependent protease cleavage from serum.\",\n      \"method\": \"Chromatography, X-ray crystallography (1.9 Å), redox conversion assays, Smad1/5/8 phosphorylation kinetics, protease susceptibility assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with biochemical and signaling assays in one rigorous study\",\n      \"pmids\": [\"25237187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BMP9 potently suppresses FSH-induced progesterone production in rat granulosa cells via a receptor complex of ALK1 and BMPR-II, activating Smad1/5/8 phosphorylation and Id-1 transcription; actions are not mediated by ALK2, ALK3, or ALK6 based on inhibitor analysis.\",\n      \"method\": \"Rat primary granulosa cell culture, ALK inhibitors, extracellular domain receptor constructs for receptor identification, Smad1/5/8 phosphorylation assay, cAMP measurement, steroidogenic gene expression\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological and molecular tools, receptor ECD blocking, single lab\",\n      \"pmids\": [\"25527306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BMP9 and BMP10 are required for ductus arteriosus closure; Bmp9-KO mice show imperfect DA closure, and combined BMP10 neutralization causes reopening. The mechanism involves a defect in intimal cell differentiation from endothelium to mesenchyme with lack of extracellular matrix deposition; several genes involved in this process are regulated by BMP9 and BMP10.\",\n      \"method\": \"Bmp9-KO mice, neutralizing anti-BMP10 antibody, transmission electron microscopy, immunofluorescence, gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus antibody neutralization in vivo with multiple mechanistic readouts\",\n      \"pmids\": [\"26056270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DLL4/Notch1 and BMP9/ALK1 signaling pathways are interdependent for induction of endothelial quiescence: canonical BMP9 signaling via ALK1-Smad1/5/9 is disrupted by Notch inhibition, and DLL4 activity is suppressed when basal ALK1-Smad pathway is inhibited. The combined pathway acts through P27KIP1 induction and thrombospondin-1 upregulation. Loss of Dll4 in vivo leads to compensatory upregulation of pSmad1/5/9.\",\n      \"method\": \"Human endothelial cell culture, Notch inhibitors, ALK1-Smad pathway inhibitors, proteomics, Dll4(+/-) mouse lung endothelial cell analysis\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway inhibition plus in vivo genetic model, single lab\",\n      \"pmids\": [\"26471266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BMP9-induced endothelial quiescence requires endoglin expression; endoglin regulates subcellular localization of zyxin in focal adhesions in response to BMP9. BMP9-dependent nuclear localization of YAP1 (Hippo pathway transcriptional coactivator) occurs via endoglin, modulating expression of CCN1, CCN2, and CCL2.\",\n      \"method\": \"RNA knockdown of endoglin, confocal immunofluorescence of zyxin/YAP1 localization, gene expression analysis (YAP1 target genes)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with direct localization imaging and gene expression, single lab\",\n      \"pmids\": [\"25909848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BMP9 induces EPC-to-endothelial cell differentiation and neovascularization via ALK1; blockade of ALK1 signaling impairs EPC-mediated neovascularization in a hindlimb ischemia model.\",\n      \"method\": \"Gene expression profiling of EPCs, in vitro ALK1-dependent differentiation assay, hindlimb ischemia mouse model, ALK1 signaling blockade\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo mechanistic studies with ALK1 pathway blockade, single lab\",\n      \"pmids\": [\"26229139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In ovarian and breast epithelial cells, GDF2/BMP9 activates the SMAD1/5 signaling axis through increased complex formation between ALK3/ALK6 (type I receptors) and BMPRII (type II receptor); this activation promotes anoikis sensitivity and suppresses anchorage-independent growth, independent of SMAD2 cross-talk. GDF2 promoter methylation silences this tumor-suppressive function in cancer cell lines.\",\n      \"method\": \"Receptor co-immunoprecipitation, SMAD1/5 phosphorylation assays, anchorage-independent growth assays, promoter methylation analysis\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor complex co-IP with functional anoikis assays, single lab\",\n      \"pmids\": [\"26678910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the human endoglin ectodomain in complex with BMP9 resolved; BMP9 interacts with a hydrophobic surface of the N-terminal orphan domain of endoglin. The interface involves HHT1-mutated residues and overlaps with the TRC105 antibody epitope. Structurally, two endoglin copies embrace homodimeric BMP9 in a manner compatible with type I but not type II receptor binding.\",\n      \"method\": \"X-ray crystallography of ENG ectodomain and ENG:BMP9 complex\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with direct mapping of disease-relevant interface residues and receptor compatibility\",\n      \"pmids\": [\"28564608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BMP9 stimulates ET-1 release from human pulmonary artery endothelial cells via Smad1 and p38 MAPK, independent of the canonical Smad4 pathway; ALK1 or BMPR-II knockdown attenuates BMP9-stimulated ET-1 release. BMP9-induced ET-1 is involved in inhibition of endothelial cell migration and promotion of tubule formation.\",\n      \"method\": \"Western blot, RT-PCR, ELISA, siRNA knockdown of ALK1 and BMPR-II, migration assay, tubule formation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple functional assays, single lab\",\n      \"pmids\": [\"22299030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BMP9 promotes liver fibrosis via SMAD/ID1 signaling directly in hepatic stellate cells; hepatic stellate cells (quiescent and activated) are identified as major BMP9-producing cells in the liver. Adenovirus-mediated Bmp9 knockdown or BMP9 antagonist ALK1-Fc attenuates fibrosis in chronic liver injury mouse models.\",\n      \"method\": \"Primary liver cell culture, BMP9 stimulation of HSCs and hepatocytes, partial hepatectomy and CCl4 mouse models, adenoviral Bmp9 knockdown, anti-BMP9 monoclonal antibody, SMAD signaling western blot\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple in vitro and in vivo models with genetic and antibody-based loss of function, identifying HSCs as the cellular source\",\n      \"pmids\": [\"28336518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BMP9/ALK1 signaling prevents hyperglycemia-induced vascular permeability by preventing VEGF-induced VE-cadherin phosphorylation and by inducing occludin expression; ALK1 haploinsufficiency worsens vascular leakage in diabetic mice, and adenoviral BMP9 delivery reduces retinal barrier dysfunction.\",\n      \"method\": \"In vitro hyperglycemic endothelial cell model, streptozotocin diabetic mouse model, Alk1 haploinsufficient mice, adenoviral BMP9 delivery, VE-cadherin phosphorylation western blot, occludin expression assay\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models with defined molecular mechanism, single lab\",\n      \"pmids\": [\"29880487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BMP9-induced osteoblastic differentiation in MSCs requires functional Notch signaling; Notch inhibitor and dominant-negative Notch1 inhibit BMP9-induced osteogenic differentiation in vitro and ectopic bone formation in vivo. BMP9 upregulates expression of Notch receptors and ligands at the intermediate stage of osteogenic differentiation, while early-responsive BMP9 target genes are not affected by Notch disruption.\",\n      \"method\": \"Notch inhibitor treatment, dominant-negative Notch1 expression, Notch pathway genetic disruption, in vivo ectopic bone formation, gene expression analysis\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic disruption with in vivo validation, single lab\",\n      \"pmids\": [\"30353129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Soluble endoglin (sENG) purified from human placenta and plasma is primarily monomeric; monomeric sENG binds circulating prodomain-bound BMP9, causing prodomain release and formation of a sENG:BMP9 complex. This complex signals with comparable potency and specificity to BMP9 alone on endothelial cells; full signaling requires transmembrane ENG. Thus sENG does not act as an inhibitory ligand trap for BMP9.\",\n      \"method\": \"Protein purification, biochemical characterization (size exclusion chromatography), in vitro endothelial cell signaling assay, prodomain release assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — protein biochemistry and functional reconstitution with purified human proteins; directly challenges prior mechanistic model\",\n      \"pmids\": [\"31431534\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of BMP9 (genetic deletion or antibody neutralization) substantially protects against chronic hypoxia-induced pulmonary hypertension in mice. BMP9 affects the balance between endothelin-1, apelin, and adrenomedullin in pulmonary endothelial cells; Bmp9-/- mice show lower ET-1 and higher apelin/ADM mRNA. BMP9-mediated vasoconstriction is inhibited by the endothelin receptor antagonist bosentan.\",\n      \"method\": \"Bmp9-/- mouse model, neutralizing anti-BMP9 antibodies, ALK1ECD ligand trap in monocrotaline/SuHx rat models, right ventricular systolic pressure measurement, in vitro human pulmonary endothelial cells, chick chorioallantoic membrane assay\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus antibody neutralization plus pharmacological rescue in multiple animal models\",\n      \"pmids\": [\"30636542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BMP9 mutations (missense) identified in IPAH patients impair BMP9 secretion and reduce anti-apoptotic activity in pulmonary arterial endothelial cells; patients with BMP9 mutations have lower plasma BMP9 levels.\",\n      \"method\": \"Exome sequencing, in vitro mutant protein expression, secretion assay, apoptosis assay in PAECs, plasma BMP9 ELISA\",\n      \"journal\": \"The European respiratory journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assays for secretion and anti-apoptosis, single study\",\n      \"pmids\": [\"30578397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structures of BMP10:ALK1 complex (2.3 Å) and prodomain-bound BMP9:ALK1 complex (3.3 Å) reveal a tripartite recognition mechanism defining BMP9/BMP10 specificity for ALK1. Introduction of BMP10-specific residues into BMP9 yields ligands with diminished C2C12 signaling, validating the mechanism. Crossveinless 2 is predicted and experimentally confirmed not to inhibit BMP9.\",\n      \"method\": \"X-ray crystallography (2.3 Å and 3.3 Å), mutagenesis (BMP10 residues introduced into BMP9), C2C12 signaling assay, in vivo bone formation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures combined with mutagenesis and functional validation in vitro and in vivo\",\n      \"pmids\": [\"32238803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF2 missense mutations found in PAH patients cause impaired BMP9 cellular processing and secretion; patients carrying these mutations have reduced plasma BMP9 levels and reduced BMP activity. Unexpectedly, plasma BMP10 levels are also markedly reduced in individuals with GDF2 mutations.\",\n      \"method\": \"In vitro mutant BMP9 protein expression, secretion assay, plasma ELISA for BMP9 and BMP10, endothelial Smad signaling bioassay\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro protein processing and functional assays with patient plasma validation, single lab\",\n      \"pmids\": [\"31661308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BMP9 and BMP10 act directly on vascular smooth muscle cells (VSMCs) via ALK1 to induce and maintain the contractile state; combined genetic inactivation of Bmp9 and Bmp10 causes decreased systemic blood pressure and diminished VSMC layer. ALK1 deletion in VSMCs recapitulates the Bmp9/10 phenotype in pulmonary but not aortic arteries, indicating vessel-bed specific receptor combinations.\",\n      \"method\": \"Cell-type specific conditional KO mouse models, blood pressure measurement, pulmonary VSMC isolation and phenotypic analysis, single molecule FISH, bulk RNA-seq, Smad7 VSMC-specific overexpression\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional transgenic mouse models with physiological readouts and transcriptomic analyses\",\n      \"pmids\": [\"33334130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BMP9-induced ALK1 endocytosis in endothelial cells is mediated by caveolin-1 (CAV-1) and dynamin-2 (DNM2) but not clathrin; knockdown of CAV-1 reduces BMP9-mediated ALK1 internalization, BMP9-dependent Smad1/5 signaling and gene expression. BMP9 treatment strongly reduces LDL transcytosis via ALK1 internalization.\",\n      \"method\": \"Endothelial cell imaging, siRNA knockdown of CAV-1/DNM2/clathrin, SMAD1/5 phosphorylation western blot, LDL transcytosis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple functional readouts (signaling and LDL transcytosis), single lab\",\n      \"pmids\": [\"33097593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRISPR-mediated BMP9 ablation in mice causes hepatosteatosis due to downregulated PPARα expression and reduced fatty acid oxidation; BMP9 activates PPARα promoter activity via p-Smad signaling. AAV-mediated BMP9 overexpression in mouse liver relieves liver steatosis.\",\n      \"method\": \"CRISPR BMP9 knockout mice, lipid accumulation assays, PPARα promoter activity assay, p-Smad western blot, PPARα antagonist GW6471, AAV-mediated overexpression\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO and AAV rescue with defined molecular mechanism (PPARα/p-Smad), multiple approaches\",\n      \"pmids\": [\"33246954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BMP9 and BMP10 repress basal CCL2 expression and release from human pulmonary artery and aortic endothelial cells via ALK1, co-dependent on ACTR-IIA and BMPR-II, and requiring Smad4; Smad1/5 signaling contributes only at near-circulating BMP9 concentrations.\",\n      \"method\": \"siRNA knockdown of ALK1, ACTR-IIA, BMPR-II, Smad4; Smad1/5 inhibition; CCL2 ELISA; Smad signaling western blot\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic siRNA receptor dissection with functional CCL2 readout, single lab\",\n      \"pmids\": [\"32576665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Endogenous circulating BMP9 is a pulmonary endothelial-protective factor that maintains vascular barrier function; BMP9 neutralization in mice increases lung vascular permeability, interstitial edema, and neutrophil extravasation. During LPS-induced lung injury, circulating BMP9 is markedly reduced due to decreased hepatic BMP9 mRNA and increased elastase activity. Exogenous BMP9 prevents LPS-induced lung injury.\",\n      \"method\": \"BMP9-neutralizing antibody in mice, lung vascular permeability assay, neutrophil extravasation measurement, murine acute lung injury (inhaled LPS) model, hepatic BMP9 mRNA quantification, plasma elastase activity, patient plasma BMP9 ELISA\",\n      \"journal\": \"American journal of respiratory and critical care medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic/antibody loss-of-function, in vivo rescue, and human patient validation in one study\",\n      \"pmids\": [\"33320799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Homozygous GDF2 nonsense mutations result in undetectable plasma BMP9 and BMP10 levels, demonstrating that loss of circulating BMP9 also abolishes circulating BMP10; heterozygous carriers have reduced but functional BMP9/BMP10 levels. Alternate translation at Met57 in one nonsense mutant does not yield secreted functional BMP9.\",\n      \"method\": \"Plasma ELISA for BMP9 and BMP10, endothelial BRE-luciferase reporter serum bioassay, in vitro mutant protein expression and secretion assay\",\n      \"journal\": \"Molecular genetics & genomic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient plasma assays combined with in vitro protein expression studies, single lab\",\n      \"pmids\": [\"33834622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BMP9 reduces osteoblast senescence by activating Smad1, which suppresses STAT1 transcriptional activity and thereby inhibits P21 expression and SASP production; this Smad1-Stat1-P21 axis mediates BMP9's protection against age-related bone loss in aged mice.\",\n      \"method\": \"Aged mouse model, Smad1 signaling inhibition in vivo, Stat1 and P21 expression analysis, SASP markers, bone mass measurement\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo inhibition of pathway with molecular readouts, single lab\",\n      \"pmids\": [\"35523787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BMP9-ID1 signaling promotes EpCAM-positive HCC cancer stem cell properties via enhancing Wnt/β-catenin signaling; ID1 knockdown represses BMP9-promoted HCC-CSC properties. BMP receptor inhibitors (K02288, LDN-212854) block BMP9-ID1 signaling and suppress HCC tumor growth in vivo.\",\n      \"method\": \"siRNA knockdown of ID1, BMP receptor inhibitor treatment, EpCAM/ID1 expression, in vivo HCC xenograft, Wnt/β-catenin signaling assay\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA, pharmacological inhibition, and in vivo model, single lab\",\n      \"pmids\": [\"33834612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXF1 transcription factor activates BMP9/ACVRL1/SMAD1 signaling in pulmonary endothelial progenitor cells; FOXF1 synergizes with ETS transcription factor FLI1 to activate the ACVRL1 promoter. Nanoparticle-mediated ACVRL1 silencing in newborn mice decreases neonatal lung angiogenesis, and exogenous BMP9 restores angiogenesis in ACVRL1-deficient and Foxf1 mutant mice.\",\n      \"method\": \"scRNA-seq, Foxf1 mutant mice (ACDMPV model), ACVRL1 promoter activation assay, nanoparticle siRNA knockdown in neonatal mice, BMP9 rescue treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transcriptomic pathway identification with genetic mouse models, nanoparticle silencing, and BMP9 rescue\",\n      \"pmids\": [\"35440116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BMP10 is the critical physiological ligand for ENG-ALK1 arteriovenous network formation, while BMP9 has limited compensatory function; Bmp10-iKO mice develop AVMs while Bmp9-KO mice show no noticeable vascular defects. BMP10 protein (but not BMP9 protein) prevents retinal AVM in Bmp9/10-dKO and endothelial Eng-iKO mice.\",\n      \"method\": \"Conditional Bmp10-iKO and Bmp9/10-dKO mouse models, retinal vascular morphometry, brain/skin AVM analysis, BMP9 and BMP10 protein rescue injections\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — comparative genetic models and protein rescue experiments directly dissecting BMP9 vs BMP10 contributions\",\n      \"pmids\": [\"36348215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BMP9 and BMP10 activate a non-canonical transcriptional SMAD-dependent MAPK pathway (MEKK4/GADD45β/P38) in endothelial cells, which is required for expression of GADD45β; activated P38 phosphorylates HSP27 and Eps15, and regulates specific gene expression (E-selectin, hyaluronan synthase 2, COX-2). BMP10 induces G1 cell cycle arrest by modulating CDK4/6 pathway and inhibiting E2F2, cyclinD1, cyclinA1 mRNA expression.\",\n      \"method\": \"Large-scale phosphoproteomics, western blot validation of phosphosites, RT-qPCR, flow cytometry cell cycle analysis\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — unbiased phosphoproteomics with western blot and functional validation, single lab\",\n      \"pmids\": [\"38439036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A heterozygous GDF2 variant causes HHT with pulmonary AVMs; in vitro, the mutant construct expresses the proprotein but lacks active mature BMP9 dimer, indicating the mutation disrupts correct protein cleavage. Plasma BMP9 levels in patients are significantly lower than controls.\",\n      \"method\": \"In vitro mutant BMP9 expression, protein processing/cleavage assay, plasma BMP9 ELISA\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro protein cleavage assay with patient plasma validation, single lab\",\n      \"pmids\": [\"34904380\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GDF2/BMP9 is a liver-derived circulating homodimeric cytokine that signals by binding with high affinity to the type I receptor ALK1 (and to endoglin as a co-receptor) on vascular endothelial cells, engaging type II receptors BMPR-II and ActR-IIA to activate canonical Smad1/5/8 phosphorylation and non-canonical pathways including p38 MAPK (via GADD45β/MEKK4), maintaining endothelial quiescence, vascular barrier integrity, and smooth muscle contractility; in mesenchymal stem cells BMP9 signals through ALK1/ALK2 and Smad1/5/8 to potently drive osteogenic differentiation with cross-talk from Wnt/β-catenin, Notch, IGF/PI3K-AKT, and MAPK pathways; BMP9 activity is regulated by a redox-sensitive intermolecular disulfide bond affecting protease susceptibility, and by prodomain association that does not inhibit receptor binding; loss-of-function GDF2 mutations impair protein cleavage or secretion, reduce circulating BMP9 and BMP10, and cause pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, and vascular malformation syndromes.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GDF2/BMP9 is a liver-derived circulating homodimeric BMP-family cytokine that signals primarily through the type I receptor ALK1 (ACVRL1) with endoglin as co-receptor to maintain vascular endothelial quiescence and barrier function [#1, #4, #16]. After secretion its pro-region remains tightly bound but does not block receptor engagement, and BMP9 binds ALK1 and endoglin with high affinity while engaging type II receptors BMPR-II and ActR-IIA to drive canonical Smad1/5/8 phosphorylation and ID1 induction [#0, #1, #29]. Structural work defines a tripartite recognition mechanism conferring BMP9/BMP10 specificity for ALK1, shows that two endoglin copies embrace the BMP9 homodimer in a manner compatible with type I but not type II receptor binding, and reveals that activity and protease susceptibility are tuned by a redox-sensitive intermolecular disulfide bond [#9, #16, #24]. In endothelium BMP9 enforces quiescence and limits angiogenesis through ID1, Notch (DLL4/Jagged1/Hey), and endoglin-dependent YAP1 programs, regulates the CXCL12/CXCR4 axis, controls retinal and lymphatic vascular remodeling and ductus arteriosus closure, and preserves vascular barrier integrity in part by repressing CCL2 and modulating endothelin-1/apelin balance [#4, #5, #7, #11, #12, #13, #17, #29, #30]. Acting on vascular smooth muscle via ALK1, BMP9 and BMP10 induce and maintain the contractile state and set systemic blood pressure [#26], and a non-canonical SMAD-dependent MEKK4/GADD45β/p38 MAPK arm controls additional endothelial gene expression and cell-cycle outputs [#36]. In mesenchymal cells BMP9 potently drives osteogenic differentiation through Smad1/5/8 with cross-talk from IGF/PI3K-AKT and Notch signaling and protects against osteoblast senescence via a Smad1-STAT1-P21 axis [#3, #20, #32], while in liver it is produced by hepatic stellate cells, promotes fibrosis via SMAD/ID1, and regulates lipid metabolism through PPARα [#18, #28]. Loss-of-function GDF2 mutations impair BMP9 cleavage or secretion, reduce circulating BMP9 and BMP10, and cause pulmonary arterial hypertension and hereditary hemorrhagic telangiectasia with vascular malformations [#23, #25, #31, #37]; conversely, BMP9 loss protects against chronic hypoxia-induced pulmonary hypertension, reflecting context-dependent roles [#22].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing how BMP9 is structured and which receptor it uses defined the molecular starting point for all downstream signaling work.\",\n      \"evidence\": \"X-ray crystallography at 2.3 Å, SPR binding, and ligand-trap cell assays identifying ALK1 as a BMP9 receptor\",\n      \"pmids\": [\"15851468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the receptor stoichiometry or type II receptor identity\", \"Pro-region's physiological role left undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defining the endothelial receptor repertoire and functional output showed BMP9 acts as an anti-angiogenic, quiescence-promoting ligand.\",\n      \"evidence\": \"Receptor-binding in COS cells plus Smad1/5, ID1, and endothelial proliferation/migration and in vivo angiogenesis assays\",\n      \"pmids\": [\"17311849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional program incompletely mapped\", \"In vivo vascular requirement not yet genetically tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Cross-talk inputs to BMP9 osteogenic signaling were identified, showing IGF-2/PI3K-AKT potentiates Smad nuclear translocation.\",\n      \"evidence\": \"ALP, Smad reporter, immunofluorescence, PI3K inhibition, and ectopic bone formation in MSCs; separate work in cholinergic neurons via ALK1\",\n      \"pmids\": [\"20499340\", \"20554873\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanistic dissection\", \"Direct biochemical link between AKT and Smad complex not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Genetic and antibody loss-of-function established BMP9 as an in vivo regulator of vascular remodeling and the CXCL12/CXCR4 axis.\",\n      \"evidence\": \"Bmp9-KO and neutralizing antibody in mice, retinal morphometry, microarray/MS, endoglin/ALK1 siRNA, hindlimb ischemia\",\n      \"pmids\": [\"22566602\", \"23018639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Apelin/Notch regulation mechanism not fully resolved\", \"Endoglin-dependence detail single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"BMP9's roles expanded to lymphatic maturation and hepatocellular autocrine survival signaling, broadening its functional scope.\",\n      \"evidence\": \"Bmp9-KO lymphatic morphometry and LEC assays; siRNA and ligand-trap proliferation/apoptosis assays in HepG2\",\n      \"pmids\": [\"23741013\", \"23936038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tumor relevance of HepG2 autocrine signaling not validated in vivo\", \"Valve gene regulation mechanism not detailed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The redox-controlled disulfide isoform and receptor/Smad requirements for VSMC and granulosa responses clarified how BMP9 activity is tuned and transduced.\",\n      \"evidence\": \"1.9 Å crystal structure and redox/protease assays; ALK1/Smad4 siRNA in VSMC calcification; ALK1/BMPR-II in granulosa cells\",\n      \"pmids\": [\"25237187\", \"25297851\", \"25527306\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological enzyme controlling the redox switch not identified\", \"VSMC calcification relevance in vivo not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mechanistic integration of BMP9 with Notch, YAP1/endoglin, and EPC differentiation programs revealed how quiescence and neovascularization outputs are coordinated, alongside a tumor-suppressive role in epithelial cells.\",\n      \"evidence\": \"Notch and ALK1-Smad inhibitor combinations, endoglin siRNA with zyxin/YAP1 imaging, EPC differentiation with ALK1 blockade, receptor co-IP and anoikis assays\",\n      \"pmids\": [\"26471266\", \"25909848\", \"26229139\", \"26678910\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pathway interdependence largely single-lab pharmacology\", \"ALK3/ALK6 usage in epithelium contrasts with endothelial ALK1 and is not reconciled\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"BMP9 and BMP10 were shown to cooperatively drive ductus arteriosus closure via endothelial-to-mesenchymal differentiation.\",\n      \"evidence\": \"Bmp9-KO with anti-BMP10 neutralization, TEM, immunofluorescence, gene expression\",\n      \"pmids\": [\"26056270\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ECM/differentiation genes mediating closure not pinpointed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The endoglin:BMP9 crystal structure mapped a disease-relevant binding interface and clarified that endoglin engagement is compatible only with type I receptor binding.\",\n      \"evidence\": \"X-ray crystallography of ENG ectodomain and ENG:BMP9 complex; non-canonical Smad1/p38 ET-1 release in PAECs; HSC-derived BMP9 driving liver fibrosis\",\n      \"pmids\": [\"28564608\", \"22299030\", \"28336518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How endoglin presents BMP9 to type II receptors mechanistically unresolved\", \"Source of circulating vs local BMP9 contributions not fully separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"BMP9/ALK1 was established as a barrier-protective signal in diabetic vasculature and a Notch-dependent osteogenic driver.\",\n      \"evidence\": \"Hyperglycemic endothelial model, STZ diabetic and Alk1 haploinsufficient mice, AAV BMP9 delivery; Notch inhibitor and dominant-negative Notch1 in MSC osteogenesis\",\n      \"pmids\": [\"29880487\", \"30353129\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"VE-cadherin/occludin regulation mechanism single lab\", \"Notch intermediate-stage requirement not biochemically defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Patient genetics and protein biochemistry linked GDF2 loss-of-function to pulmonary hypertension while redefining soluble endoglin as a signaling partner rather than an inhibitory trap; paradoxically, BMP9 loss protected against hypoxic PH.\",\n      \"evidence\": \"Exome sequencing with secretion/apoptosis assays in PAECs; purified sENG:BMP9 reconstitution; Bmp9-KO/antibody/ALK1ECD across multiple PH models\",\n      \"pmids\": [\"30578397\", \"31431534\", \"30636542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protective vs causative roles of BMP9 in PH not mechanistically reconciled\", \"sENG complex physiological abundance unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Structural specificity, receptor internalization, VSMC contractility control, hepatic metabolism, and the BMP9/BMP10 interdependence in mutation carriers were defined, yielding a systems-level view.\",\n      \"evidence\": \"BMP9/BMP10:ALK1 crystal structures with mutagenesis; CAV-1/DNM2 endocytosis and LDL transcytosis assays; conditional Bmp9/Bmp10 and VSMC-Alk1 KO with blood pressure; CRISPR BMP9-KO hepatosteatosis with PPARα; CCL2 receptor dissection; GDF2 mutation plasma BMP9/BMP10 ELISA\",\n      \"pmids\": [\"32238803\", \"33097593\", \"33334130\", \"33246954\", \"32576665\", \"31661308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Vessel-bed-specific receptor combinations only partially mapped\", \"Mechanism coupling BMP9 loss to BMP10 reduction unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Circulating BMP9 was confirmed as a barrier-protective factor in lung injury, with mutation studies and FOXF1 transcriptional control further defining its production and downstream programs, plus roles in osteoblast senescence and HCC stemness.\",\n      \"evidence\": \"Anti-BMP9 antibody and LPS lung injury with patient plasma; nonsense-mutation plasma ELISA/bioassay; FOXF1/FLI1 ACVRL1 promoter and neonatal lung models; Smad1-STAT1-P21 in aged mice; BMP9-ID1 Wnt in HCC\",\n      \"pmids\": [\"33320799\", \"33834622\", \"35440116\", \"35523787\", \"33834612\", \"34904380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hepatic regulation of BMP9 during injury incompletely characterized\", \"FOXF1-BMP9 axis specificity beyond lung not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Comparative genetics dissected BMP9 from BMP10, showing BMP10 is the dominant physiological ENG-ALK1 ligand for arteriovenous network formation.\",\n      \"evidence\": \"Conditional Bmp10-iKO, Bmp9/10-dKO, and Eng-iKO mice with retinal/AVM morphometry and protein rescue\",\n      \"pmids\": [\"36348215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why GDF2 mutations cause HHT despite limited BMP9 vascular requirement not reconciled\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A non-canonical SMAD-dependent MEKK4/GADD45β/p38 MAPK arm was defined, expanding BMP9/BMP10 signaling beyond canonical Smad transcription.\",\n      \"evidence\": \"Phosphoproteomics with western blot validation, RT-qPCR, and cell-cycle flow cytometry in endothelial cells\",\n      \"pmids\": [\"38439036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of the p38 arm not established\", \"Single-lab phosphoproteomic dataset\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular basis for the coupled loss of circulating BMP10 when GDF2/BMP9 is mutated, and the reconciliation of BMP9's protective versus pathogenic roles across vascular beds, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mechanism linking BMP9 loss to reduced BMP10 stability/secretion\", \"Vessel-bed-specific protective vs harmful BMP9 effects not unified\", \"Therapeutic targeting window in PAH/HHT undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 16, 24]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 8, 17, 29]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 22, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 18, 30, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 8, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 7, 11, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [22, 23, 25, 37]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [26, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ACVRL1\", \"ENG\", \"BMPR2\", \"ACVR2A\", \"BMP10\", \"ACVR1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}